AstraZeneca
Johanna Baxter Excerpts(1 day, 16 hours ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Johanna Baxter (Paisley and Renfrewshire South) (Lab)
I declare an interest as the chair of the all-party parliamentary group on vulnerable groups to pandemics. More than 1.2 million clinically vulnerable people are still shielding from covid because their mRNA vaccine does not provide efficient protection for immunosuppressed people. Will my hon. Friend set out how the Department is putting the UK at the forefront of international R&D in life sciences to support those very vulnerable people?
Chris Bryant
Not only have we set aside £520 million precisely to be able to invest in the life sciences industry with an innovation fund, we are very keen to work with specific businesses to understand how they can make more secure, long-term investment. The single most important thing for most people making an investment in the UK is whether they believe there is political, fiscal and financial stability in the UK. That is what we are absolutely determined to deliver. My hon. Friend makes a very good point about those who are immunosuppressed for all sorts of different reasons, whether their medication or a condition. I will take that point back to the Department.